Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Study Details
Study Description
Brief Summary
The aim of this study is to explore whether endostar combined with NVB and DDP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2 |
Detailed Description
This study is to explore whether endostar combined with NVB and DDP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens used as second-line treatment of advanced esophageal squamous cell carcinomas
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Endostar Combined With NVB and DDP Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2 |
Drug: NVB
25mg/m2 ,D1,8
Other Names:
Drug: DDP
75mg/m2 ,D1 or 25mg/m2 D1-3
Other Names:
Drug: Endostar
15mg/d,d1-d7 civ
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Progression Free Survival [from the first cycle of treatment (day one) to two month after the last cycle]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically proven primary thoracic esophageal squamous cell carcinoma
-
According to the esophageal AJCC2009 7th to determine new stage IV esophageal cancer
-
The subject has PD after first-line chemotherapy or radiation within a year
-
Presence of at least one index lesion measurable by CT scan or MRI according to RECIST 1.1
-
Can eat more than liquid diet; No signs before esophageal perforation
-
18~75 years
-
PS:0-1
-
Life expectancy of ≥ 3 months
-
ANC ≥ 2×109/L,PLT ≥ 100×109/L,Hb ≥ 90g/L
-
TB ≤ UNL; ALT/AST ≤ 2.5×UNL,AKP ≤ 5×UNL
-
Ccr≤ UNL,Scr≥60 mL/min
-
Normal electrocardiogram (ecg), the body had no unheal wounds
-
Radiotherapy before within the scope of the normal dose and not affect subsequent treatment
-
Prior to biological agents, especially e. coli genetically engineered products without severe allergic reactions
-
Signed written informed consent
Exclusion Criteria:
-
Breast-feeding or pregnant women, no effective contraception if risk of conception exists
-
Chronic diarrhea, enteritis, intestine obstruction which are not under control
-
Esophageal obstruction cannot eat liquid completely, esophagus have deep ulcer perforation or hematemesis; Esophageal cancer common complications such as anastomotic leakage, serious lung complications, etc.
-
A second primary tumor (except skin basal cell carcinoma)
-
The original serious heart disease, including: higher risk of congestive heart failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension
-
With uncontrol nerve, mental illness or mental disorders, compliance is poor, can't cooperate with accounts and response to treatment; Primary brain tumors or CNS metastases illness did not get a control, has obvious cranial hypertension or nerve mental symptoms
-
With bleeding tendency
-
Has inherited bleeding evidence of physical or blood coagulation disorder
-
With clear chemotherapy drug allergy
-
Other researchers believe that patients should not participate in this testing
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Cancer hospital Fudan University | Shanghai | Shanghai | China | 200032 |
Sponsors and Collaborators
- Fudan University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ENDO-SH-001